Comprehensive Proteomic Analysis of Dysferlinopathy Unveiling Molecular Mechanisms and Biomarkers Linked to Pathological Progression

Di Wang, Xinyi Liu, Qifang He, Fuze Zheng, Long Chen, Ying Zheng, Minghui Zeng, Yuhua Lin, Xin Lin, H Chen, Min‐Ting Lin, Ning Wang, Zhiqiang Wang, Feng LinCNS 2024 · DOI

TL;DR

This study presents a comprehensive proteomic analysis of muscle biopsies from patients with dysferlinopathy, revealing a detailed molecular landscape of the disease and identifying key proteins that correlate with disease severity. These findings offer novel insights into the underlying mechanisms of dysferlinopathy and suggest potential biomarkers and therapeutic targets.

What Problem Does This Paper Address?

Dysferlinopathies are a group of inherited muscular dystrophies caused by mutations in the DYSF gene, leading to impaired muscle membrane repair. While previous studies have explored the functional role of dysferlin, a complete understanding of the molecular mechanisms driving the disease, especially across varying pathological stages, has been limited. Existing proteomic studies were often constrained by low resolution and the limited number of differentially expressed proteins identified. This paper aims to address this gap by employing a high-resolution proteomic approach to comprehensively analyze the protein profiles of dysferlinopathy muscles and correlate these findings with histopathological changes, thereby uncovering new insights into disease progression and potential therapeutic avenues.

Methods

The researchers utilized a multi-faceted approach to analyze muscle biopsies from 15 patients with dysferlinopathy and 21 age-matched controls. Key techniques included:

  • Tandem Mass Tag (TMT)-labeled Liquid Chromatography-Mass Spectrometry (LC-MS/MS)-based Proteomics: This high-resolution technique was used to quantify protein expression levels. The method involved extensive sample pre-fractionation to enhance analytical depth, allowing for the quantification of over 1500 proteins.
  • Protein-Protein Interaction (PPI) Network Analysis: STRING and Cytoscape were used to construct and analyze networks of interacting proteins, identifying key protein clusters and modules.
  • Weighted Gene Co-Expression Network Analysis (WGCNA): This method was employed to identify modules of co-expressed genes/proteins that are associated with DYSF expression in normal muscle tissue.
  • Differential Protein Analysis: The limma package was used to identify significantly differentially expressed proteins between dysferlinopathy and normal muscle tissues.
  • Functional Enrichment Analysis: Tools like clusterProfiler were used to determine the biological significance of the identified protein sets, focusing on Gene Ontology (GO) and REACTOME pathways.
  • Muscle Immunofluorescence and Western Blot Analysis: These techniques were used to validate the expression levels and localization of specific proteins identified in the proteomic analysis, correlating them with clinical and histopathological data.

Datasets

The study utilized muscle biopsy samples from 15 patients with dysferlinopathy and 21 age-matched control subjects. Clinical and molecular data for the patients, including sex, age of onset, muscle phenotypes, CK levels, mutation details, and histopathology grading scores, were collected and are presented in Table 1. RNA expression data for DYSF in various human tissues was obtained from the Human Protein Atlas. Mutation entries for DYSF in LGMD were sourced from the Human Gene Mutation Database.

Key Insights and Ideas

  • Unveiling a Broad Proteomic Landscape: The study successfully quantified over 1500 proteins in dysferlinopathy muscle, representing a significant expansion compared to previous studies. This comprehensive dataset provides a detailed molecular snapshot of the disease.
  • Correlation Between Protein Expression and Disease Severity: A crucial insight is the strong correlation found between the expression levels of specific proteins (Annexins A1, A2, A4, A5, LMNA, and PYGM) and the histopathological grading scale of dysferlinopathy. This suggests these proteins could serve as valuable biomarkers for disease progression.
  • Identification of Dysregulated Pathways: The proteomic analysis revealed dysregulation across numerous cellular pathways, including mRNA metabolic processes, regulated exocytosis, immune response, muscle system processes, and calcium transmembrane transport, offering a deeper understanding of the disease's molecular underpinnings.
  • Annexins as Key Players: The study highlights the significant upregulation of several annexin family proteins (A1, A2, A4, A5) in dysferlinopathy muscles, with their expression levels correlating with disease severity. This suggests a compensatory role or involvement in the pathological process.
  • Impaired Energy Metabolism: Downregulation of key enzymes involved in glycogen metabolism, such as PYGM and GPD1, was observed, indicating potential perturbations in energy metabolism within affected muscles.

Key Results

  • 1600 Differentially Expressed Proteins: The study identified 1600 differentially expressed proteins in dysferlinopathy muscle compared to normal tissue, with 1321 showing increased expression and 279 showing decreased expression.
  • Significant Correlations with Histopathology: Proteins like ANXA1, ANXA2, ANXA4, ANXA5, LMNA, and PYGM showed significant positive correlations with histopathology grading scale, fiber size variability, necrosis/regeneration, interstitial fibrosis, and inflammation.
  • Validation of Biomarkers: Immunofluorescence and immunoblotting confirmed the altered expression of Annexins and Lamin A/C, showing increased levels in patients with higher histopathology scores.
  • Inflammation and Immune Response: The proteomic data supported previous findings of upregulated proteins related to immune response and complement activation in dysferlinopathy.

Limitations and Future Work

  • Technical Challenges: The authors acknowledge the inherent technical challenges in analyzing skeletal muscle proteomics due to the abundance of structural proteins.
  • Correlation vs. Causation: While strong correlations were identified, further research is needed to establish direct causal relationships between the identified proteins and disease progression.
  • Further Investigation of Energy Metabolism: The study noted potential impairments in glycogen metabolism but suggested that further investigation is required to fully understand these processes.
  • Therapeutic Target Development: The identified proteins and pathways offer promising avenues for future therapeutic interventions, which will require further validation and drug development efforts. The authors propose that their findings could lead to novel diagnostic and therapeutic strategies for dysferlinopathy.

Summary updated

Abstract

Through the aggregation of expression data from dysferlinopathy-impacted muscles exhibiting a range of pathological alterations, we identified multiple key proteins associated with the dystrophic pathology of patients with dysferlinopathy. These findings provide novel insights into the pathogenesis of dysferlinopathy and propose promising targets for future therapeutic endeavors.
BibTeX
@inproceedings{wang2024comprehensive,
  author = {Di Wang and Xinyi Liu and Qifang He and Fuze Zheng and Long Chen and Ying Zheng and Minghui Zeng and Yuhua Lin and Xin Lin and H Chen and Min‐Ting Lin and Ning Wang and Zhiqiang Wang and Feng Lin},
  title = {{Comprehensive Proteomic Analysis of Dysferlinopathy Unveiling Molecular Mechanisms and Biomarkers Linked to Pathological Progression}},
  booktitle = {CNS},
  year = {2024},
  doi = {10.1111/cns.70065},
}
Figure